Quote | Connect Biopharma Holdings Limited (NASDAQ:CNTB)
Last: | $1.33 |
---|---|
Change Percent: | -0.75% |
Open: | $1.35 |
Close: | $1.33 |
High: | $1.41 |
Low: | $1.28 |
Volume: | 43,786 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Connect Biopharma Holdings Limited (NASDAQ:CNTB)
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Message Board Posts | Connect Biopharma Holdings Limited (NASDAQ:CNTB)
Subject | By | Source | When |
---|---|---|---|
Connect Biopharma (NASDAQ:$CNTB) was downgraded by analysts at | conix | investorshub | 05/05/2022 9:13:59 PM |
Dipping some toes in the water here | ErnieBilco | investorshub | 05/04/2022 3:31:17 PM |
CNTB Chart | conix | investorshub | 11/20/2021 3:54:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Connect Biopharma Holdings Limited Website:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...